bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S5 from Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Authors: Li Dapeng , Chi Yihebali , Chen Xiaohong , Ge Minghua , Zhang Yuan , Guo Zhuming , Wang Jun , Chen Jie , Zhang Jiewu , Cheng Ying , Li Zhendong , Liu Hui , Qin Jianwu , Zhu Jingqiang , Cheng Ruochuan , Xu Zhengang , Zheng Xiangqian , Tang Pingzhang , Gao Ming
Published: April 2023

Changes of quality of life between baseline and different time point of assessment evaluated by EORTC QLQ-C30
Supplementary Materials from Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans
Authors: Stadlbauer Andreas , Kinfe Thomas M. , Eyüpoglu Ilker , Zimmermann Max , Kitzwögerer Melitta , Podar Klaus , Buchfelder Michael , Heinz Gertraud , Oberndorfer Stefan , Marhold Franz
Published: April 2023

Supplementary Methods, Figures, and Tables
Figure S3 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Authors: Mehrvarz Sarshekeh Amir , Alshenaifi Jumanah , Roszik Jason , Manyam Ganiraju C. , Advani Shailesh M. , Katkhuda Riham , Verma Anuj , Lam Michael , Willis Jason , Shen John Paul , Morris Jeffrey , Davis Jennifer S. , Loree Jonathan M. , Lee Hey Min , Ajani Jaffer A. , Maru Dipen M. , Overman Michael J. , Kopetz Scott
Published: April 2023

Supplementary Fig S3. Association of gene size and the differential expression of IFN-γ pathway in genes commonly mutated in MSS CRC
Supplementary Figure S3 from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Authors: Zaccaria Gian Maria , Bertamini Luca , Petrucci Maria Teresa , Offidani Massimo , Corradini Paolo , Capra Andrea , Romano Alessandra , Liberati Anna Marina , Mannina Donato , de Fabritiis Paolo , Cascavilla Nicola , Ruggeri Marina , Mina Roberto , Patriarca Francesca , Benevolo Giulia , Belotti Angelo , Gaidano Gianluca , Nagler Arnon , Hájek Roman , Spencer Andrew , Sonneveld Pieter , Musto Pellegrino , Boccadoro Mario , Gay Francesca
Published: April 2023

Figure S3. Univariate analysis to predict ER18 comparing DS-ERMM High and Int vs. Low
Figure S2 from Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Authors: Jacobs Samuel A. , Lee James J. , George Thomas J. , Wade James L. , Stella Philip J. , Wang Ding , Sama Ashwin R. , Piette Fanny , Pogue-Geile Katherine L. , Kim Rim S. , Gavin Patrick G. , Lipchik Corey , Feng Huichen , Wang Ying , Finnigan Melanie , Kiesel Brian F. , Beumer Jan H. , Wolmark Norman , Lucas Peter C. , Allegra Carmen J. , Srinivasan Ashok
Published: April 2023

Figure SF2: cfDNA mutational analysis cfDNA from plasma collected upon enrollment was analyzed for mutations with a 74-gene Guardant panel (1). Alterations were identified in 30 genes as shown in the figure. Patient IDs: Green=Stable Disease, Red=Progressive Disease, and Black=non-evaluable. Specific patients are discussed below and in the main text.
Supplementary Methods from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

Supplementary Methods
Figure S1 from Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Authors: Jacobs Samuel A. , Lee James J. , George Thomas J. , Wade James L. , Stella Philip J. , Wang Ding , Sama Ashwin R. , Piette Fanny , Pogue-Geile Katherine L. , Kim Rim S. , Gavin Patrick G. , Lipchik Corey , Feng Huichen , Wang Ying , Finnigan Melanie , Kiesel Brian F. , Beumer Jan H. , Wolmark Norman , Lucas Peter C. , Allegra Carmen J. , Srinivasan Ashok
Published: April 2023

Figure SF1 Representative IHC and CISH data are shown. HER2 status is negative in the primary tissue (A) but is amplified in the metastatic tissue collected upon enrollment into FC-7, based on CISH (C) and IHC staining (B) with the antibody from Ventana.
Supplementary Data from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Authors: Tuscano Joseph M. , Poh Christina , Kaesberg Paul , Luxardi Guilluame , Merleev Alexander , Marusina Alina , Brunson Ann , Rosenberg Aaron , Jonas Brian , Maverakis Emanual
Published: April 2023

Supplemental figure legends
Supplementary Figure S8 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

WGS-predictions, ROC
Supplemental Figure 1 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Authors: Tuscano Joseph M. , Poh Christina , Kaesberg Paul , Luxardi Guilluame , Merleev Alexander , Marusina Alina , Brunson Ann , Rosenberg Aaron , Jonas Brian , Maverakis Emanual
Published: April 2023

Plasma cytokine levels of LTCR responders compared to all other patients.
Supplementary Figure S12 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

Heterogeneity of genomic scar score, NGS
Supplementary Figure S11 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

Heterogeneity of genomic scar score (SNP-array based dataset)
Table S1 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Antibodies used for phenotyping and sorting of myeloma cells
Figure S3 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Annotation of single cells based on origin
Figure S12 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Transcriptional activation of oxidative phosphorylation pathway genes in DP6 dabrafenib-persistent cells
Supplementary Figure S3 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
Authors: Hollebecque Antoine , Chung Hyun C. , de Miguel Maria J. , Italiano Antoine , Machiels Jean-Pascal , Lin Chia-Chi , Dhani Neesha C. , Peeters Marc , Moreno Victor , Su Wu-Chou , Chow Kay Hoong , Galvao Violeta R. , Carlsen Michelle , Yu Danni , Szpurka Anna M. , Zhao Yumin , Schmidt Shelly L. , Gandhi Leena , Xu Xiaojian , Bang Yung-Jue
Published: April 2023

Figure S3. Pharmacokinetics for the anti-PD-L1 antibody LY3300054 alone and in combination with anti-TIM-3 antibody.
Supplementary Data from A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Authors: Lassman Andrew B. , Wen Patrick Y. , van den Bent Martin J. , Plotkin Scott R. , Walenkamp Annemiek M.E. , Green Adam L. , Li Kai , Walker Christopher J. , Chang Hua , Tamir Sharon , Henegar Leah , Shen Yao , Alvarez Mariano J. , Califano Andrea , Landesman Yosef , Kauffman Michael G. , Shacham Sharon , Mau-Sørensen Morten
Published: April 2023

Supplementary Data from A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Supplementary Data from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

Supplementary table 1-9
Supplementary Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Authors: Esteban-Fabró Roger , Willoughby Catherine E. , Piqué-Gili Marta , Montironi Carla , Abril-Fornaguera Jordi , Peix Judit , Torrens Laura , Mesropian Agavni , Balaseviciute Ugne , Miró-Mur Francesc , Mazzaferro Vincenzo , Pinyol Roser , Llovet Josep M.
Published: April 2023

Supplementary Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Figure S3 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

Lollipop plots of putative driver genes
Supplemental Figure 2 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Authors: Sheng Xinan , Chen Haige , Hu Bin , Yao Xudong , Liu Ziling , Yao Xin , Guo Hongqian , Hu Yi , Ji Zhigang , Luo Hong , Shi Benkang , Liu Jiyan , Wu Jin , Zhou FangJian , He Zhisong , Fan Jinhai , Wang Weifeng , Feng Hui , Yao Sheng , Keegan Patricia , Huang Yiran , Guo Jun
Published: April 2023

CONSORT diagram for the Phase II study.
Supplementary Data from Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Authors: Börcsök Judit , Sztupinszki Zsofia , Bekele Raie , Gao Sizhi P. , Diossy Miklos , Samant Amruta S. , Dillon Kasia M. , Tisza Viktoria , Spisák Sándor , Rusz Orsolya , Csabai Istvan , Pappot Helle , Frazier Zoë J. , Konieczkowski David J. , Liu David , Vasani Naresh , Rodrigues James A. , Solit David B. , Hoffman-Censits Jean H. , Plimack Elizabeth R. , Rosenberg Jonathan E. , Lazaro Jean-Bernard , Taplin Mary-Ellen , Iyer Gopa , Brunak Søren , Lozsa Rita , Van Allen Eliezer M. , Szüts Dávid , Mouw Kent W. , Szallasi Zoltan
Published: April 2023

Supplementary Methods
Supplementary Figure S3 from Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma
Authors: Chahoud Jad , Gleber-Netto Frederico O. , McCormick Barrett Z. , Rao Priya , Lu Xin , Guo Ming , Morgan Maggaret B. , Chu Randy A. , Martinez-Ferrer Magaly , Eterovic Agda Karina , Pickering Curtis R. , Pettaway Curtis A.
Published: April 2023

Figure S3 - Tumor mutation burden among TCGA tumors and PSCC. Whole exome sequenced tumors from TCGA and the PSCC samples are represented in this plot. Tumor mutation burden (y-axis) was determined by the number of mutations per megabase based on a sequencing coverage of 50 Mb for TCGA tumors and 64 Mb for PSCC. PSCC samples presented an intermediate TMB when compared to all tumor types from TCGA. The total number of samples per tumor type is represented in upper axis. SKCM - Skin Cutaneous Melanoma; LUSC - Lung squamous cell carcinoma; LUAD - Lung adenocarcinoma; BLCA - Bladder Urothelial Carcinoma; COAD - Colon adenocarcinoma; DLBC - Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; STAD - Stomach adenocarcinoma; ESCA - Esophageal carcinoma; HNSC - Head and Neck squamous cell carcinoma; READ - Rectum adenocarcinoma; CESC - Cervical squamous cell carcinoma and endocervical adenocarcinoma; LIHC - Liver hepatocellular carcinoma; UCEC - Uterine Corpus Endometrial Carcinoma; OV - Ovarian serous cystadenocarcinoma; KIRP - Kidney renal papillary cell carcinoma; GBM - Glioblastoma multiforme; KIRC - Kidney renal clear cell carcinoma; PSCC - Penile carcinoma; UCS - Uterine Carcinosarcoma; SARC - Sarcoma; BRCA - Breast invasive carcinoma; CHOL -Cholangiocarcinoma ; PAAD - Pancreatic adenocarcinoma; LGG - Brain Lower Grade Glioma; MESO - Mesothelioma; ACC - Adrenocortical carcinoma; PRAD - Prostate adenocarcinoma; KICH - Kidney Chromophobe; TGCT - Testicular Germ Cell Tumors; THYM - Thymoma; LAML - Acute Myeloid Leukemia; UVM - Uveal Melanoma; THCA - Thyroid carcinoma; PCPG - Pheochromocytoma and Paraganglioma.
sTable 1, sTable 2, sTable 3, sFigure 1, sFigure 2, sFigure 3, sFigure 4 from The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Authors: Manjunath Shwetha H. , Cohen Adam D. , Lacey Simon F. , Davis Megan M. , Garfall Alfred L. , Melenhorst J. Joseph , Maxwell Russell , Arscott W. Tristram , Maity Amit , Jones Joshua A. , Plastaras John P. , Stadtmauer Edward A. , Levine Bruce L. , June Carl H. , Milone Michael C. , Paydar Ima
Published: April 2023

sTable 1 shows radiation characteristics of Group A, B, and C. sTable 2 shows characteristics of CART-BCMA cells during manufacturing and at peak expansion in vivo in Group A, B, and C. sTable 3 shows details of radiation received after CART-BCMA therapy. sFigure 1 shows soluble BCMA serum levels before cyclophosphamide lymphodepletion on Day -3. sFigure 2 shows that prior radiation exposure is not associated with the level of CART-BCMA cells in vivo at peak expansion. sFigure 3 shows radiation was not associated with the level of persistent CART-BCMA cells in peripheral blood at Day 28. sFigure 4 shows level of CART-BCMA cells at peak expansion and Day 28 correlated with clinical response, and within responders, receipt of prior radiation was not associated with differences in CART=BCMA levels.
Supplementary Table S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Clinical Characteristics of patients imaged with [18F]DASA-23
Figure S5 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure 5. Relative expression levels of lucitanib-specific RTK targets and ligands in PDX and patient tumors. A) mRNA expression levels of 2544 genes detected by HTG in Pt325 samples (Pre-tt versus On-tt). Highlighted are some differentially expressed genes between both samples, including FGFR1. Data is log-2 transformed. B) and C) Relative mRNA levels of lucitanib-specific RTK targets or cognate ligands in PDX and patient tumors from the MTKI/FGFRi-treated patient cohort from Figure 3D, respectively.
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
Supplementary Figure S10 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Imaging of IC-4
Figure S3 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure 3. FGFR1-4 and FGF3/4/19 CN and mRNA levels in BC. A) Proportion of BCs harboring FGFR1-4 amplification in five cohorts of primary (TCGA, METABRIC and MSK) or metastatic tumors (INSERM and The Metastatic Breast Cancer Project). Data was acquired from cBioPortal (cbioportal.org/datasets). B) Correlation analysis between FGFR1-4 CN and mRNA levels in the TCGA BC cohort. Pearson correlation coefficient (r2) is shown. C) and D) FGFR1 and 11q13 (FGF3/4/19 and CCND1) CN co-amplification analysis in the VHIO and TCGA BC cohorts, respectively. Red bars denote cases with 11q13 amplification and blue bars FGFR1 amplification. Statistical test: Fisher's exact test. E) and F) FGFR1 and FGF mRNA co-expression analysis in the VHIO and TCGA BC cohorts, respectively. Statistical test: Sidak's multiple comparisons test.
Figure S1 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure 1. FGFR1-4 DNA CN, mRNA levels and ROC curves analysis. A) Waterfall plot representing the best antitumor response of FGFRi in 24 patients from 8 different cancer types treated at VHIO. FGFR1/2 amplification status and high FGFR1-4 mRNA levels are indicated in the underneath panel. B) Copy number (CN) values of FGFR1-4 by MSK-IMPACT in the FGFR/FGFamp PDX collection and categorized analysis in PDXs harboring CN amplification (CN>4), according to the response to rogaratinib (responders (SD and PR) and non-responders (PD)). C) Evaluation of FGFR1/4 CN ratio by FISH ratio (the dashed line indicates the CN ratio>2.2 that is considered amplified) and categorized analysis according to the response to rogaratinib. D) Correlation analysis between the CN values (X-axis) and mRNA levels (Y-axis) of FGFR1-4 obtained from MSK-IMPACT or nCounter, respectively. Pearson correlation coefficient (r2) is shown. E) Categorized analysis of FGFR1-4 mRNA composite biomarker according to the response to rogaratinib, obtained from HTG or qPCR data. Statistical test: Mann-Whitney U test. ROC curve analysis the FGFR1-4 mRNA composite biomarker, obtained from HTG or qPCR (AUC=0.89, both).
Supplementary Data from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
Authors: Larkin James R. , Anthony Susan , Johanssen Vanessa A. , Yeo Tianrong , Sealey Megan , Yates Abi G. , Smith Claire Friedemann , Claridge Timothy D.W. , Nicholson Brian D. , Moreland Julie-Ann , Gleeson Fergus , Sibson Nicola R. , Anthony Daniel C. , Probert Fay
Published: April 2023

Supplementary Data from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
Supplementary Figure S6 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Figure S6 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Supplementary Data from Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
Authors: Viganò Lucia , Locatelli Alberta , Ulisse Adele , Galbardi Barbara , Dugo Matteo , Tosi Diego , Tacchetti Carlo , Daniele Tiziana , Győrffy Balázs , Sica Lorenzo , Macchini Marina , Zambetti Milvia , Zambelli Stefania , Bianchini Giampaolo , Gianni Luca
Published: April 2023

Supplementary Data from Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Authors: Marmouset Vincent , Decroocq Justine , Garciaz Sylvain , Etienne Gabriel , Belhabri Amine , Bertoli Sarah , Gastaud Lauris , Simand Célestine , Chantepie Sylvain , Uzunov Madalina , Genthon Alexis , Berthon Céline , Chiche Edmond , Dumas Pierre-Yves , Vargaftig Jacques , Salmeron Géraldine , Lemasle Emilie , Tavernier Emmanuelle , Delage Jérémy , Loirat Marion , Morineau Nadine , Blanc-Durand Félix , Pautier Patricia , Vergé Véronique , Auger Nathalie , Thomas Myrtille , Stefani Laetitia , Lepelley Marion , Boyer Thomas , Thepot Sylvain , Gourin Marie-Pierre , Bourquard Pascal , Duchmann Matthieu , Morice Pierre-Marie , Michallet Mauricette , Adès Lionel , Fenaux Pierre , Récher Christian , Dombret Hervé , Pagès Arnaud , Marzac Christophe , Leary Alexandra , Micol Jean-Baptiste
Published: April 2023

Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and platelet counts from patients referred for cytopenia exploration after OC exposed to a PARPi treatment according to t-MN diagnosis (“t-MN”) or not (“Cytopenia”).
Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Authors: Hall MacLean S. , Mullinax John E. , Cox Cheryl A. , Hall Amy M. , Beatty Matthew S. , Blauvelt Jamie , Innamarato Patrick , Nagle Luz , Branthoover Holly , Wiener Doris , Schachner Benjamin , Martinez Alberto J. , Richards Allison D. , Rich Carolyn J. , Colón Colón Marjorie , Schell Michael J. , Teer Jamie K. , Khushalani Nikhil I. , Weber Jeffrey S. , Mulé James J. , Sondak Vernon K. , Pilon-Thomas Shari , Sarnaik Amod A.
Published: April 2023

Supplementary Table 1 shows the distribution of Grade 3 and 4 non-hematologic adverse events reported in this study.
Supplementary Figure from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Authors: Lee Iris K. , Noguera-Ortega Estela , Xiao Zebin , Todd Leslie , Scholler John , Song Decheng , Liousia Maria , Lohith Katheryn , Xu Kexiang , Edwards Kimberly J. , Farwell Michael D. , June Carl H. , Albelda Steven M. , Puré Ellen , Sellmyer Mark A.
Published: April 2023

Supplementary Figure from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Supplementary Table from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
Authors: Chiang Nai-Jung , Tan Kien Thiam , Bai Li-Yuan , Hsiao Chin-Fu , Huang Chung-Yu , Hung Yi-Ping , Huang Chien-Jui , Chen San-Chi , Shan Yan-Shen , Chao Yee , Huang Yi-Hsiang , Lee I-Cheng , Lee Pei-Chang , Su Yung-Yeh , Chen Shu-Jen , Yeh Chun-Nan , Chen Li-Tzong , Chen Ming-Huang
Published: April 2023

Supplementary Table from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
Supplementary Figure from p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness
Authors: Rodriguez-Ramirez Christie , Zhang Zhaocheng , Warner Kristy A. , Herzog Alexandra E. , Mantesso Andrea , Zhang Zhixiong , Yoon Eusik , Wang Shaomeng , Wicha Max S. , Nör Jacques E.
Published: April 2023

Supplementary Figure from p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Authors: Lee Sung-Eun , Wang Feng , Grefe Maison , Trujillo-Ocampo Abel , Ruiz-Vasquez Wilfredo , Takahashi Koichi , Abbas Hussein A. , Borges Pamella , Antunes Dinler Amaral , Al-Atrash Gheath , Daver Naval , Molldrem Jeffrey J. , Futreal Andrew , Garcia-Manero Guillermo , Im Jin S.
Published: March 2023

Purpose:

The aim of this study is to determine immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy (IMT, αCTLA-4, and/or αPD-1 antibodies) and/or hypomethylating agent (HMA).

Experimental Design:

Peripheral blood samples from 55 patients with MDS were assessed for immune subsets, T-cell receptor (TCR) repertoire, mutations in 295 acute myeloid leukemia (AML)/MDS-related genes, and immune-related gene expression profiling before and after the first treatment.

Results:

Clinical responders treated with IMT ± HMA but not HMA alone showed a significant expansion of central memory (CM) CD8+ T cells, diverse TCRβ repertoire pretreatment with increased clonality and emergence of novel clones after the initial treatment, and a higher mutation burden pretreatment with subsequent reduction posttreatment. Autophagy, TGFβ, and Th1 differentiation pathways were the most downregulated in nonresponders after treatment, while upregulated in responders. Finally, CTLA-4 but not PD-1 blockade attributed to favorable changes in immune landscape.

Conclusions:

Analysis of tumor–immune landscape in MDS during immunotherapy provides clinical response biomarkers.
Supplementary Fig. from Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays
Authors: Boyd Zachary S. , Wu Qun Jenny , O'Brien Carol , Spoerke Jill , Savage Heidi , Fielder Paul J. , Amler Lukas , Yan Yibing , Lackner Mark R.
Published: April 2023

Supplementary Fig. from Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays
Supplementary Fig from Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts
Authors: Di Cello Francescopaolo , Hillion Joelle , Kowalski Jeanne , Ronnett Brigitte M. , Aderinto Abimbola , Huso David L. , Resar Linda M.S.
Published: April 2023

Supplementary Fig from Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts
Supplementary Figure 2 from Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria
Authors: Zeng Jin , Sun Yi , Wu Kaijie , Li Lei , Zhang Gang , Yang Zenglei , Wang Zhiqiang , Zhang Dong , Xue Yan , Chen Yule , Zhu Guodong , Wang Xinyang , He Dalin
Published: April 2023

Supplementary Figure 2 from Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria
Supplementary Fig from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
Authors: Flanagan James M. , Funes Juan M. , Henderson Stephen , Wild Laurence , Carey Nessa , Boshoff Chris
Published: April 2023

Supplementary Fig from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
Supplementary Figure 1 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Authors: Hage-Sleiman Rouba , Herveau Stéphanie , Matera Eva-Laure , Laurier Jean-Fabien , Dumontet Charles
Published: April 2023

Supplementary Figure 1 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Supplementary Figure 4 from Modulation of drug resistance by artificial transcription factors
Authors: Blancafort Pilar , Tschan Mario P. , Bergquist Sharon , Guthy Daniel , Brachat Arndt , Sheeter Dennis A. , Torbett Bruce E. , Erdmann Dirk , Barbas Carlos F.
Published: April 2023

Supplementary Figure 4 from Modulation of drug resistance by artificial transcription factors
Supplementary Fig. S3 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Authors: Gonzales Andrea J. , Hook Kenneth E. , Althaus Irene W. , Ellis Paul A. , Trachet Erin , Delaney Amy M. , Harvey Patricia J. , Ellis Teresa A. , Amato Danielle M. , Nelson James M. , Fry David W. , Zhu Tong , Loi Cho-Ming , Fakhoury Stephen A. , Schlosser Kevin M. , Sexton Karen E. , Winters R. Thomas , Reed Jessica E. , Bridges Alex J. , Lettiere Daniel J. , Baker Deborah A. , Yang Jianxin , Lee Helen T. , Tecle Haile , Vincent Patrick W.
Published: April 2023

Supplementary Fig. S3 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Supplementary Figure 9 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Authors: Tripathi Rakshamani , Samadder Tanmoy , Gupta Sarika , Surolia Avadhesha , Shaha Chandrima
Published: April 2023

Supplementary Figure 9 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Supplementary Fig. S2 from A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1α
Authors: Li Shan Hua , Shin Dong Hoon , Chun Yang-Sook , Lee Myung Kyu , Kim Myung-Suk , Park Jong-Wan
Published: April 2023

Supplementary Fig. S2 from A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1α
Supplementary Table S4 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Table S4 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Table 1, Figures 1-4 from ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Authors: Williamson Chris T. , Muzik Huong , Turhan Ali G. , Zamò Alberto , O'Connor Mark J. , Bebb D. Gwyn , Lees-Miller Susan P.
Published: April 2023

Supplementary Table 1, Figures 1-4 from ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Supplementary Data from Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Authors: Yoon Young-Kwang , Kim Hwang-Phill , Han Sae-Won , Hur Hyung-Seok , Oh Do Youn , Im Seock-Ah , Bang Yung-Jue , Kim Tae-You
Published: April 2023

Supplementary Data from Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Supplementary Figure 1, Tables 1-4 from JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
Authors: Manthey Carl L. , Johnson Dana L. , Illig Carl R. , Tuman Robert W. , Zhou Zhao , Baker Judith F. , Chaikin Margery A. , Donatelli Robert R. , Franks Carol F. , Zeng Lee , Crysler Carl , Chen Yanmin , Yurkow Edward J. , Boczon Lisa , Meegalla Sanath K. , Wilson Kenneth J. , Wall Mark J. , Chen Jinsheng , Ballentine Shelley K. , Ott Heidi , Baumann Christian , Lawrence Danielle , Tomczuk Bruce E. , Molloy Christopher J.
Published: April 2023

Supplementary Figure 1, Tables 1-4 from JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
Supplementary Fig. S3 legend from Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Authors: Kuo Po-Lin , Ni Wen-Chiu , Tsai Eing-Mei , Hsu Ya-Ling
Published: April 2023

Supplementary Fig. S3 legend from Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Supplementary Fig. S3 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Authors: Abouantoun Thamara J. , MacDonald Tobey J.
Published: April 2023

Supplementary Fig. S3 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Supplementary Fig. S1 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Authors: Leyton Julius , Smith Graham , Lees Mark , Perumal Meg , Nguyen Quang-de , Aigbirhio Franklin I. , Golovko Oksana , He Quimin , Workman Paul , Aboagye Eric O.
Published: April 2023

Supplementary Fig. S1 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Authors: Weisberg Ellen , Choi Hwan Geun , Barrett Rosemary , Zhou Wenjun , Zhang Jianming , Ray Arghya , Nelson Erik A. , Jiang Jingrui , Moreno Daisy , Stone Richard , Galinsky Ilene , Fox Edward , Adamia Sophia , Kung Andrew L. , Gray Nathanael S. , Griffin James D.
Published: April 2023

Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Table S1 from Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma
Authors: Hegde Ganapati V. , Munger Corey M. , Emanuel Katy , Joshi Avadhut D. , Greiner Timothy C. , Weisenburger Dennis D. , Vose Julie M. , Joshi Shantaram S.
Published: April 2023

Supplementary Table S1 from Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma
Supplementary Data from Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma Is Mediated by BCL2
Authors: Tang Jian-Zhong , Kong Xiang-Jun , Kang Jian , Fielder Graeme C. , Steiner Michael , Perry Jo K. , Wu Zheng-Sheng , Yin Zhinan , Zhu Tao , Liu Dong-Xu , Lobie Peter E.
Published: April 2023

Supplementary Data from Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma Is Mediated by BCL2
Supplementary Table 3 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Authors: Wei Ping , Walls Marlena , Qiu Ming , Ding Richard , Denlinger Robert H. , Wong Anthony , Tsaparikos Kosta , Jani Jitesh P. , Hosea Natilie , Sands Michelle , Randolph Sophia , Smeal Tod
Published: April 2023

Supplementary Table 3 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Supplementary Figures 1-4 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Authors: Wei Ping , Walls Marlena , Qiu Ming , Ding Richard , Denlinger Robert H. , Wong Anthony , Tsaparikos Kosta , Jani Jitesh P. , Hosea Natilie , Sands Michelle , Randolph Sophia , Smeal Tod
Published: April 2023

Supplementary Figures 1-4 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Supplementary Figure 2 from Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells
Authors: Rahman Ruman , Osteso-Ibanez Teresa , Hirst Robert A. , Levesley Jane , Kilday John-Paul , Quinn Siobhan , Peet Andrew , O'Callaghan Chris , Coyle Beth , Grundy Richard G.
Published: April 2023

Supplementary Figure 2 from Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells
Supplementary Figure 3 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
Authors: Sabbatini Peter , Korenchuk Susan , Rowand Jason L. , Groy Arthur , Liu Qi , Leperi Dominic , Atkins Charity , Dumble Melissa , Yang Jingsong , Anderson Kelly , Kruger Ryan G. , Gontarek Richard R. , Maksimchuk Kenneth R. , Suravajjala Sapna , Lapierre Russell R. , Shotwell J. Brad , Wilson Joseph W. , Chamberlain Stanley D. , Rabindran Sridhar K. , Kumar Rakesh
Published: April 2023

Supplementary Figure 3. A. Time course of IGF-1R inhibition in vivo. B. Effect of GSK1838705A on IGF-1R signaling in vivo.
Supplementary Tables from Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Authors: Ariazi Eric A. , Leitão Andrei , Oprea Tudor I. , Chen Bin , Louis Teresa , Bertucci Anne Marie , Sharma Catherine G.N. , Gill Shaun D. , Kim Helen R. , Shupp Heather A. , Pyle Jennifer R. , Madrack Alexis , Donato Anne L. , Cheng Dong , Paige James R. , Jordan V. Craig
Published: April 2023

Supplementary Tables from Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Supplementary Fig. S2 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
Authors: Moretti Luigi , Kim Kwang Woon , Jung Dae Kwang , Willey Christopher D. , Lu Bo
Published: April 2023

Supplementary Fig. S2 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
Supplementary Fig. S2 from EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line
Authors: Fukai Junya , Yokote Hideyuki , Yamanaka Ryuya , Arao Tokuzo , Nishio Kazuto , Itakura Toru
Published: April 2023

Supplementary Fig. S2 from EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line
Supplementary Table H from Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
Authors: Petalidis Lawrence P. , Oulas Anastasis , Backlund Magnus , Wayland Matthew T. , Liu Lu , Plant Karen , Happerfield Lisa , Freeman Tom C. , Poirazi Panayiota , Collins V. Peter
Published: April 2023

Supplementary Table H from Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
Supplementary Table F from Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
Authors: Petalidis Lawrence P. , Oulas Anastasis , Backlund Magnus , Wayland Matthew T. , Liu Lu , Plant Karen , Happerfield Lisa , Freeman Tom C. , Poirazi Panayiota , Collins V. Peter
Published: April 2023

Supplementary Table F from Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
Supplementary Table S2 from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Authors: Hu Shuiying , Niu Hongmei , Minkin Patton , Orwick Shelley , Shimada Akira , Inaba Hiroto , Dahl Gary V.H. , Rubnitz Jeffrey , Baker Sharyn D.
Published: April 2023

Supplementary Table S2 from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Supplementary Table S1 from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Authors: Hu Shuiying , Niu Hongmei , Minkin Patton , Orwick Shelley , Shimada Akira , Inaba Hiroto , Dahl Gary V.H. , Rubnitz Jeffrey , Baker Sharyn D.
Published: April 2023

Supplementary Table S1 from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Supplementary Figure Legends 1- 4 from miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation
Authors: Boni Valentina , Bitarte Nerea , Cristobal Ion , Zarate Ruth , Rodriguez Javier , Maiello Evaristo , Garcia-Foncillas Jesus , Bandres Eva
Published: April 2023

Supplementary Figure Legends 1- 4 from miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation
Supplementary Figure 3 from miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation
Authors: Boni Valentina , Bitarte Nerea , Cristobal Ion , Zarate Ruth , Rodriguez Javier , Maiello Evaristo , Garcia-Foncillas Jesus , Bandres Eva
Published: April 2023

Supplementary Figure 3 from miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation
Supplementary Methods and Legends from Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Authors: Breuleux Madlaina , Klopfenstein Matthieu , Stephan Christine , Doughty Cheryl A. , Barys Louise , Maira Saveur-Michel , Kwiatkowski David , Lane Heidi A.
Published: April 2023

Supplementary Methods and Legends from Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Authors: Augustine Christina K. , Toshimitsu Hiroaki , Jung Sin-Ho , Zipfel Patricia A. , Yoo Jin S. , Yoshimoto Yasunori , Selim M. Angelica , Burchette James , Beasley Georgia M. , McMahon Nicole , Padussis James , Pruitt Scott K. , Ali-Osman Francis , Tyler Douglas S.
Published: April 2023

Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Figure 2 from Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Authors: Breuleux Madlaina , Klopfenstein Matthieu , Stephan Christine , Doughty Cheryl A. , Barys Louise , Maira Saveur-Michel , Kwiatkowski David , Lane Heidi A.
Published: April 2023

Supplementary Figure 2 from Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Supplementary Figure Legends from Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis
Authors: Chen Ying , Hao Hua , He Songqing , Cai Lei , Li Yongsheng , Hu Shunze , Ye Duyun , Hoidal John , Wu Ping , Chen Xiaoping
Published: April 2023

Supplementary Figure Legends from Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis